Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 146

1.

Computational approach for deriving cancer progression roadmaps from static sample data.

Sun Y, Yao J, Yang L, Chen R, Nowak NJ, Goodison S.

Nucleic Acids Res. 2017 Jan 20. pii: gkx003. doi: 10.1093/nar/gkx003. [Epub ahead of print]

PMID:
28108658
2.

Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells.

Sankpal UT, Goodison S, Jones-Pauley M, Hurtado M, Zhang F, Basha R.

Oncotarget. 2017 Jan 14. doi: 10.18632/oncotarget.14651. [Epub ahead of print]

3.

A microRNA biomarker panel for the non-invasive detection of bladder cancer.

Urquidi V, Netherton M, Gomes-Giacoia E, Serie DJ, Eckel-Passow J, Rosser CJ, Goodison S.

Oncotarget. 2016 Dec 27;7(52):86290-86299. doi: 10.18632/oncotarget.13382.

4.

Urinary mRNA biomarker panel for the detection of urothelial carcinoma.

Urquidi V, Netherton M, Gomes-Giacoia E, Serie D, Eckel-Passow J, Rosser CJ, Goodison S.

Oncotarget. 2016 Jun 21;7(25):38731-38740. doi: 10.18632/oncotarget.9587.

5.

A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort.

Goodison S, Ogawa O, Matsui Y, Kobayashi T, Miyake M, Ohnishi S, Fujimoto K, Dai Y, Shimizu Y, Tsukikawa K, Furuya H, Rosser CJ.

J Transl Med. 2016 Oct 7;14(1):287.

6.

A Nomogram Derived by Combination of Demographic and Biomarker Data Improves the Noninvasive Evaluation of Patients at Risk for Bladder Cancer.

Huang S, Kou L, Furuya H, Yu C, Goodison S, Kattan MW, Garmire L, Rosser CJ.

Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1361-6. doi: 10.1158/1055-9965.EPI-16-0260.

PMID:
27383773
7.

A multiplex immunoassay for the non-invasive detection of bladder cancer.

Shimizu Y, Furuya H, Bryant Greenwood P, Chan O, Dai Y, Thornquist MD, Goodison S, Rosser CJ.

J Transl Med. 2016 Jan 30;14:31. doi: 10.1186/s12967-016-0783-2.

8.

Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature.

Zhang G, Gomes-Giacoia E, Dai Y, Lawton A, Miyake M, Furuya H, Goodison S, Rosser CJ.

Diagn Pathol. 2014 Nov 12;9:200. doi: 10.1186/s13000-014-0200-1.

9.

Cancer progression modeling using static sample data.

Sun Y, Yao J, Nowak NJ, Goodison S.

Genome Biol. 2014 Aug 26;15(8):440. doi: 10.1186/s13059-014-0440-0.

10.

External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort.

Chen LM, Chang M, Dai Y, Chai KX, Dyrskj√łt L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, Beukers W, Lopez LE, Henrique R, Young PR, Urquidi V, Goodison S, Rosser CJ.

Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1804-12. doi: 10.1158/1055-9965.EPI-14-0029.

11.

Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.

Gomes-Giacoia E, Miyake M, Goodison S, Sriharan A, Zhang G, You L, Egan JO, Rhode PR, Parker AS, Chai KX, Wong HC, Rosser CJ.

PLoS One. 2014 Jun 4;9(6):e96705. doi: 10.1371/journal.pone.0096705.

12.

Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors.

Zhang G, Miyake M, Lawton A, Goodison S, Rosser CJ.

BMC Cancer. 2014 May 3;14:310. doi: 10.1186/1471-2407-14-310.

13.

Urinary protein biomarker panel for the detection of recurrent bladder cancer.

Rosser CJ, Chang M, Dai Y, Ross S, Mengual L, Alcaraz A, Goodison S.

Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1340-5. doi: 10.1158/1055-9965.EPI-14-0035.

14.

Simultaneous multi-analyte urinary protein assay for bladder cancer detection.

Rosser CJ, Dai Y, Miyake M, Zhang G, Goodison S.

BMC Biotechnol. 2014 Apr 1;14:24. doi: 10.1186/1472-6750-14-24.

15.

Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway.

Miyake M, Goodison S, Lawton A, Gomes-Giacoia E, Rosser CJ.

Oncogene. 2015 Feb 12;34(7):890-901. doi: 10.1038/onc.2014.2.

16.

MULTIPLEX URINARY TESTS FOR BLADDER CANCER DIAGNOSIS.

Urquidi V, Rosser CJ, Goodison S.

Eur Med J Urol. 2013;1:70-73.

17.

Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer.

Miyake M, Lawton A, Dai Y, Chang M, Mengual L, Alcaraz A, Goodison S, Rosser CJ.

BMC Cancer. 2014 Feb 13;14:86. doi: 10.1186/1471-2407-14-86.

18.

Deleted in liver cancer-1 (DLC1): an emerging metastasis suppressor gene.

Popescu NC, Goodison S.

Mol Diagn Ther. 2014 Jun;18(3):293-302. doi: 10.1007/s40291-014-0086-3. Review.

19.

PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation.

Giacoia EG, Miyake M, Lawton A, Goodison S, Rosser CJ.

Mol Cancer Res. 2014 Mar;12(3):322-34. doi: 10.1158/1541-7786.MCR-13-0543.

20.

Chemokine (C-X-C motif) ligand 1 (CXCL1) protein expression is increased in high-grade prostate cancer.

Miyake M, Lawton A, Goodison S, Urquidi V, Rosser CJ.

Pathol Res Pract. 2014 Feb;210(2):74-8. doi: 10.1016/j.prp.2013.08.013.

PMID:
24252309
Items per page

Supplemental Content

Loading ...
Support Center